Khosrow Kashfi Selected Research

nitroaspirin

7/2015	Nitric Oxide-Releasing Aspirin Suppresses NF-κB Signaling in Estrogen Receptor Negative Breast Cancer Cells in Vitro and in Vivo.
6/2010	Modulation of stress genes expression profile by nitric oxide-releasing aspirin in Jurkat T leukemia cells.
11/2009	Nitro-aspirin inhibits MCF-7 breast cancer cell growth: effects on COX-2 expression and Wnt/beta-catenin/TCF-4 signaling.
10/2005	NO-donating aspirin inhibits both the expression and catalytic activity of inducible nitric oxide synthase in HT-29 human colon cancer cells.
1/2004	NO-donating aspirin inhibits intestinal carcinogenesis in Min (APC(Min/+)) mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Khosrow Kashfi Research Topics

Disease

40	Neoplasms (Cancer) 01/2022 - 12/2002
22	Colonic Neoplasms (Colon Cancer) 12/2015 - 02/2002
13	Type 2 Diabetes Mellitus (MODY) 03/2022 - 01/2019
9	Carcinogenesis 01/2019 - 10/2003
8	Inflammation (Inflammations) 01/2022 - 11/2010
5	Body Weight (Weight, Body) 01/2022 - 10/2018
4	Hyperalgesia 12/2015 - 11/2010
4	Leukemia 03/2012 - 01/2005
3	Obesity 01/2022 - 10/2018
3	Insulin Resistance 01/2022 - 11/2017
3	Infarction (Infarctions) 01/2022 - 02/2020
3	Myocardial Ischemia (Ischemic Heart Diseases) 01/2022 - 02/2020
3	Reperfusion Injury 01/2022 - 02/2020
3	Pancreatic Neoplasms (Pancreatic Cancer) 01/2020 - 12/2002
3	Stomach Ulcer (Gastric Ulcer) 12/2015 - 04/2013
3	Breast Neoplasms (Breast Cancer) 07/2015 - 11/2009
3	Edema (Dropsy) 01/2015 - 03/2012
2	Glucose Intolerance 03/2022 - 01/2022
2	Brucellosis (Malta Fever) 03/2022 - 12/2018
2	Hyperglycemia 01/2022 - 01/2019
2	Hypoxia (Hypoxemia) 01/2022 - 01/2019
2	Osteoporosis 01/2022 - 01/2020
2	Wounds and Injuries (Trauma) 03/2021 - 10/2020
2	Triple Negative Breast Neoplasms 01/2021 - 03/2012
2	Hemorrhage 12/2015 - 12/2015
2	Adenocarcinoma 03/2012 - 04/2006
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 12/2010 - 06/2010
2	Lung Neoplasms (Lung Cancer) 01/2009 - 12/2002
2	Carcinoma (Carcinomatosis) 04/2006 - 10/2003
1	Hypercholesterolemia 05/2022
1	Myocardial Infarction 05/2022
1	Bovine Brucellosis (Bang's Disease) 03/2022
1	Neoplasm Metastasis (Metastasis) 01/2022
1	Dyslipidemias (Dyslipidemia) 01/2022
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2022
1	Hyperuricemia 01/2022
1	Ischemia 01/2022
1	Osteoporotic Fractures 01/2022
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2022
1	Alzheimer Disease (Alzheimer's Disease) 10/2021

Drug/Important Bio-Agent (IBA)

32	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2022 - 12/2002
22	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2022 - 10/2003
19	Hydrogen Sulfide (Sulfide, Hydrogen)IBA 01/2022 - 03/2012
15	nitroxy-butyl-acetylsalicylic acidIBA 07/2015 - 10/2003
13	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2022 - 02/2002
9	EnzymesIBA 01/2022 - 10/2005
9	4-(3-thioxo-3H-1,2-dithiol-5-yl)phenyl 2-((4-(nitrooxy)butanoyl)oxy)benzoateIBA 01/2020 - 03/2012
6	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 01/2022 - 11/2003
6	Pharmaceutical PreparationsIBA 01/2021 - 03/2005
6	CarrageenanIBA 12/2015 - 11/2010
5	Dinoprostone (PGE2)FDA Link 01/2022 - 07/2005
5	NitratesIBA 01/2022 - 10/2018
5	Nitric Oxide Synthase (NO Synthase)IBA 01/2022 - 11/2003
5	Sulindac (Copal)FDA LinkGeneric 12/2015 - 12/2002
5	nitroaspirinIBA 07/2015 - 01/2004
5	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 04/2006 - 11/2003
4	Messenger RNA (mRNA)IBA 01/2022 - 01/2019
4	NitritesIBA 01/2022 - 10/2020
4	CytokinesIBA 01/2022 - 06/2015
4	Analgesics (Analgesic Drugs)IBA 01/2016 - 11/2010
4	Naproxen (Naprosyn)FDA LinkGeneric 01/2015 - 12/2010
4	4-(5-thioxo-5H-1,2-dithiol-3-yl)-phenyl 2-acetoxybenzoateIBA 10/2013 - 03/2012
4	CarcinogensIBA 03/2012 - 04/2006
4	beta CateninIBA 06/2010 - 10/2003
3	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 01/2022 - 07/2005
3	Insulin (Novolin)FDA Link 01/2022 - 11/2017
3	AntipyreticsIBA 01/2016 - 11/2010
3	TCF Transcription FactorsIBA 01/2013 - 10/2003
3	Biological ProductsIBA 07/2007 - 03/2005
3	NF-kappa B (NF-kB)IBA 04/2006 - 11/2003
3	N- acetyl- S- (alpha- methyl- 4- (2- methylpropyl)benzeneacetyl)cysteine 4-(nitrooxy)butyl esterIBA 07/2004 - 12/2002
2	Glucose (Dextrose)FDA LinkGeneric 03/2022 - 01/2022
2	Attenuated VaccinesIBA 03/2022 - 12/2018
2	Streptozocin (Streptozotocin)FDA Link 10/2020 - 01/2019
2	sodium bisulfide (NaHS)IBA 09/2020 - 02/2020
2	Drinking WaterIBA 01/2020 - 01/2019
2	Caspase 3 (Caspase-3)IBA 01/2020 - 01/2013
2	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2015 - 07/2015
2	Estrogen ReceptorsIBA 07/2015 - 03/2012
2	CateninsIBA 01/2013 - 12/2010
2	Cyclin D1IBA 01/2013 - 10/2003
2	Flurbiprofen (Froben)FDA LinkGeneric 01/2013 - 06/2004
2	XenobioticsIBA 03/2012 - 01/2009
2	ProdrugsIBA 12/2010 - 11/2010
2	EicosanoidsIBA 10/2005 - 07/2005
2	Ibuprofen (Motrin)FDA LinkGeneric 06/2004 - 12/2002
2	Indomethacin (Indometacin)FDA LinkGeneric 06/2004 - 12/2002
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 05/2022
1	VaccinesIBA 03/2022
1	LipoxinsIBA 01/2022
1	CholesterolIBA 01/2022
1	oxidized low density lipoproteinIBA 01/2022
1	Carbon MonoxideIBA 01/2022
1	Lipoproteins (Lipoprotein)IBA 01/2022
1	Uric Acid (Urate)IBA 01/2022
1	sodium nitrateIBA 01/2022
1	LipidsIBA 11/2021

Therapy/Procedure

7	Therapeutics 01/2022 - 01/2009
6	Chemoprevention 01/2009 - 02/2002
1	Drug Therapy (Chemotherapy) 11/2021